Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Metrics to compare | 0A64 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship0A64PeersSector | |
---|---|---|---|---|
P/E Ratio | −0.2x | −1.6x | −0.6x | |
PEG Ratio | −0.17 | −0.02 | 0.00 | |
Price/Book | 2.6x | 3.0x | 2.6x | |
Price / LTM Sales | - | 30.0x | 3.1x | |
Upside (Analyst Target) | - | 268.6% | 55.2% | |
Fair Value Upside | Unlock | 17.9% | 9.8% | Unlock |